Results 31 to 40 of about 101,846 (359)

Synthesis, Tyrosinase Inhibiting Activity and Molecular Docking of Fluorinated Pyrazole Aldehydes as Phosphodiesterase Inhibitors

open access: yesApplied Sciences, 2019
A series of fluorinated 4,5-dihydro-1H-pyrazole derivatives were synthesized in the reaction of corresponding acetophenone and different aldehydes followed by the second step synthesis of desired compounds from synthesized chalcone, hydrazine hydrate ...
Vesna Rastija   +6 more
doaj   +1 more source

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]

open access: yesPLoS ONE, 2013
The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
Florian Rieder   +5 more
doaj   +1 more source

Cyclic AMP signalling in pancreatic islets [PDF]

open access: yes, 2010
Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian   +2 more
core   +1 more source

Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension

open access: yesCanadian Respiratory Journal, 2015
BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.
Jolene H Fisher   +4 more
doaj   +1 more source

5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6- (3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one [PDF]

open access: yes, 2018
Natural and semi-synthetic compounds are being studied as novel phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction, pulmonary hypertension, and lower urinary symptoms.
Ongaro, Alberto   +2 more
core   +1 more source

Portopulmonary hypertension practice patterns after liver transplantation

open access: yesLiver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose   +3 more
wiley   +1 more source

Two phosphodiesterases from Ustilago maydis share structural and biochemical properties with non-fungal phosphodiesterases

open access: yesFrontiers in Microbiology, 2010
The dependence of Protein Kinase A (PKA) activity on cAMP levels is an important facet of the dimorphic switch between budding and filamentous growth as well as for pathogenicity in some fungi.
Charu eAgarwal   +2 more
doaj   +1 more source

cAMP-Inhibits Cytoplasmic Phospholipase A(2) and Protects Neurons against Amyloid-beta-Induced Synapse Damage [PDF]

open access: yes, 2015
A key event in Alzheimer’s disease (AD) is the production of amyloid-β (Aβ) peptides and the loss of synapses. In cultured neurons Aβ triggered synapse damage as measured by the loss of synaptic proteins. α-synuclein (αSN), aggregates of which accumulate
Bate, C, Williams, A
core   +2 more sources

Tonic and phasic nitric oxide signals in hippocampal long-term potentiation [PDF]

open access: yes, 2006
Nitric oxide ( NO) participates in long-term potentiation (LTP) and other forms of synaptic plasticity in many different brain areas but where it comes from and how it acts remain controversial.
Garthwaite, J, Hopper, RA
core   +1 more source

Phosphodiesterase Inhibitors [PDF]

open access: yesInternational Cardiovascular Forum Journal, 2019
Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for pulmonary hypertension and erectile dysfunction.
Rui Plácido, Mitja Lainscak
openaire   +1 more source

Home - About - Disclaimer - Privacy